Article Versions Notes

Ling Z, Aini H, Kajikawa S, Shirakawa J, Tsuji K, Asou Y, Koga H, Sekiya I, Nifuji A, Noda M, et al. Osteolytic Bone Loss and Skeletal Deformities in a Mouse Model for Early-Onset Paget’s Disease of Bone with PFN1 Mutation Are Treatable by Alendronate. Pharmaceuticals. 2023; 16(10):1395. https://doi.org/10.3390/ph16101395

Ling, Zhu, Hailati Aini, Shuhei Kajikawa, Jumpei Shirakawa, Kunikazu Tsuji, Yoshinori Asou, Hideyuki Koga, Ichiro Sekiya, Akira Nifuji, Masaki Noda, and et al. 2023. "Osteolytic Bone Loss and Skeletal Deformities in a Mouse Model for Early-Onset Paget’s Disease of Bone with PFN1 Mutation Are Treatable by Alendronate" Pharmaceuticals 16, no. 10: 1395. https://doi.org/10.3390/ph16101395

Ling, Z., Aini, H., Kajikawa, S., Shirakawa, J., Tsuji, K., Asou, Y., Koga, H., Sekiya, I., Nifuji, A., Noda, M., & Ezura, Y. (2023). Osteolytic Bone Loss and Skeletal Deformities in a Mouse Model for Early-Onset Paget’s Disease of Bone with PFN1 Mutation Are Treatable by Alendronate. Pharmaceuticals, 16(10), 1395. https://doi.org/10.3390/ph16101395